Payment overview · 2025
General Payments
$602.74
49 reported records · 13 companies
Healthcare provider profile · identity verified
David J Starkey
Allopathic & Osteopathic Physicians|Family Medicine · HUTCHINSON, KS · NPI 1548233844
Verified facts
What the public records show
CMS Open Payments records show David J Starkey received $602.74 in general payments during 2025 across 49 reported records.
Novo Nordisk Inc accounted for 31.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $190.88 | 31.7% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $149.10 | 24.7% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.47 | 7.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.01 | 6.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.16 | 4.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.07 | 4.5% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $25.61 | 4.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $24.30 | 4.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.39 | 3.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.80 | 2.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $15.31 | 2.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.89 | 2.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.75 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $602.74 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $168.39 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $153.73 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.83 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.47 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.47 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.93 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.01 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $28.76 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.76 | 5 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $27.07 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 108 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
108 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 25 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 837 | 191 |
| Atorvastatin Calcium | Atorvastatin Calcium | 672 | 178 |
| Pantoprazole Sodium | Pantoprazole Sodium | 517 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 467 | 119 |
| Losartan Potassium | Losartan Potassium | 447 | 114 |
| Omeprazole | Omeprazole | 386 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 82 |
| Lisinopril | Lisinopril | 302 | 79 |
| Potassium Chloride | Potassium Chloride | 302 | 63 |
| Montelukast Sodium | Montelukast Sodium | 273 | 66 |
| Metformin Hcl Er | Metformin Hcl | 270 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 269 | 62 |
| Valsartan | Valsartan | 226 | 56 |
| Gabapentin | Gabapentin | 213 | 48 |
| Furosemide | Furosemide | 197 | 51 |
| Simvastatin | Simvastatin | 186 | 41 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 184 | 56 |
| Finasteride | Finasteride | 172 | 40 |
| Sertraline Hcl | Sertraline Hcl | 168 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 40 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 152 | 38 |
| Ozempic | Semaglutide | 151 | 22 |
| Warfarin Sodium | Warfarin Sodium | 151 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 37 |
| Atenolol | Atenolol | 128 | 38 |
| Glimepiride | Glimepiride | 127 | 36 |
| Trazodone Hcl | Trazodone Hcl | 126 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 29 |
| Eliquis | Apixaban | 123 | 25 |
| Metformin Hcl | Metformin Hcl | 113 | 28 |
| Meloxicam | Meloxicam | 110 | 31 |
| Mounjaro | Tirzepatide | 108 | 16 |
| Alprazolam | Alprazolam | 107 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 104 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 18 |
| Allopurinol | Allopurinol | 87 | 27 |
| Terazosin Hcl | Terazosin Hcl | 87 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 72 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 81 | 74 |
| Sucralfate | Sucralfate | 81 | 23 |
| Tramadol Hcl | Tramadol Hcl | 81 | 34 |
| Famotidine | Famotidine | 80 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 22 |
| Bupropion Xl | Bupropion Hcl | 78 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 78 | 20 |
| Carvedilol | Carvedilol | 77 | 25 |
| Pregabalin | Pregabalin | 75 | 26 |
| Nebivolol Hcl | Nebivolol Hcl | 73 | 26 |
| Prednisone | Prednisone | 71 | 53 |
| Azithromycin | Azithromycin | 66 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 17 |
| Myrbetriq | Mirabegron | 55 | 11 |
| Celecoxib | Celecoxib | 54 | 14 |
| Clonidine Hcl | Clonidine Hcl | 52 | 11 |
| Colestipol Hcl | Colestipol Hcl | 50 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 19 |
| Megestrol Acetate | Megestrol Acetate | 46 | 14 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Clonazepam | Clonazepam | 44 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 11 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 41 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Clarithromycin | Clarithromycin | 40 | 38 |
| Donepezil Hcl | Donepezil Hcl | 40 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 39 | suppressed |
| Klor-Con M20 | Potassium Chloride | 39 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Amoxicillin | Amoxicillin | 36 | 20 |
| Spironolactone | Spironolactone | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Linzess | Linaclotide | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 22 |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 17 |
| Primidone | Primidone | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 14 | suppressed |
| Acetic Acid | Acetic Acid | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Felbatol | Felbamate | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Keppra | Levetiracetam | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $602.74 · 49 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AUSTEDO XR, Auvelity, COMIRNATY, CREON, GEMTESA, INTELLIS ADAPTIVESTIM, LINZESS, MOUNJARO, NURTEC ODT, Omnipod, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error